# EmpowHER-303 (zanidatamab): what clinicians are saying

> 49 statements from 10 sources (3 videos, 6 posts, 1 registry record), 28 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
- NCT ID: NCT06435429
- Registry: https://clinicaltrials.gov/study/NCT06435429
- Sponsor: Jazz Pharmaceuticals
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: zanidatamab
- Indication: metastatic HER2-positive breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: 4d062849615bbfa1373c947708df575e89b62641d712882733775298276fc6b4

## Counts

- Commentary sources screened: 18
- Sources cited by verified statements: 10
- Verified statements: 49
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 28
- Findings: 7
- Named people in screened sources (unnamed speakers and accounts not counted): 8
- Speakers cited: 8
- Cited speakers with a verified identity: 8
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 3
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 3
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Medical oncology
  - 1 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A physician described in the sources as presenting EmpowHER-303 sees treatment after T-DXd as unsettled, while identifying chemotherapy plus trastuzumab as a usual option. Their rationale for studying zanidatamab rests on earlier combination activity, which does not establish benefit in this setting. The sources reviewed for this edition contain no trial outcome data to judge added benefit or tolerability.

## Findings (titles)

- F1. Post-T-DXd treatment: why speakers look to EmpowHER-303 for answers
  - 8 statements from 3 speakers in 4 sources, 2 of them podcasts or videos.
  - 3 of the 3 named speakers in this finding hold this view.
  - 2 of the report's 3 cited clinicians.
- F2. EmpowHER-303: what speakers say
  - 4 statements from 1 speaker in 3 sources, 2 of them podcasts or videos.
  - 1 of the report's 3 cited clinicians.
- F3. Zanidatamab: why a clinician links dual-site HER2 binding to possible benefit
  - 6 statements from 1 speaker in 2 sources, all podcasts or videos.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 3 cited clinicians.
- F4. EmpowHER-303 participation: why a clinician advises discussion and eligibility support
  - 8 statements from 1 speaker in 3 sources, all podcasts or videos.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 3 cited clinicians.
- F5. Trials: a clinician advises more talks; a speaker welcomes expected Brazil entry
  - 9 statements from 2 speakers in 4 sources, 3 of them podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “a speaker welcomes expected Brazil entry”.
  - 1 of the report's 3 cited clinicians.

### Beyond the trial population

- F6. Earlier zanidatamab data: what speakers highlight in antitumor activity
  - 8 statements from 4 speakers in 5 sources, 1 of them a podcast or video.
  - 4 of the 4 named speakers in this finding hold this view.
  - 1 of the report's 3 cited clinicians.
- F7. HER2+ care: why a speaker weighs timing, resistance and lasting toxicity
  - 4 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

2 of the 7 findings and 10 of the 49 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 8 | 5 | 4 | 3 | 2 |
| F2 | 4 | 3 | 3 | 1 | 2 |
| F3 | 6 | 3 | 2 | 1 | 2 |
| F4 | 8 | 4 | 3 | 1 | 4 |
| F5 | 9 | 7 | 4 | 2 | 2 |
| F6 | 8 | 5 | 5 | 4 | 4 |
| F7 | 4 | 1 | 1 | 1 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 3 | 2 | 1 | 0 | 2 | 9 | 0 | 2 posts and articles, 2 podcasts and video |
| F2 | 0 | 1 | 0 | 0 | 3 | 5 | 0 | 2 podcasts and video, 1 registry |
| F3 | 4 | 0 | 0 | 0 | 2 | 6 | 0 | 2 podcasts and video |
| F4 | 1 | 0 | 0 | 0 | 7 | 9 | 0 | 3 podcasts and video |
| F5 | 7 | 0 | 1 | 0 | 1 | 9 | 1 | 1 post or article, 3 podcasts and video |
| F6 | 5 | 0 | 0 | 0 | 3 | 8 | 0 | 4 posts and articles, 1 podcast or video |
| F7 | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR): no finding draws on it directly
- Secondary endpoints: no finding draws on it directly
- Population and setting: F1 (3 shared claims), F2 (1 shared claims), F4 (4 shared claims)
- The comparison: F1 (3 shared claims), F2 (3 shared claims), F3 (1 shared claims), F4 (1 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (1 shared claims), F4 (1 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (1 shared claims), F4 (5 shared claims), F5 (1 shared claims)

## Abbreviations

- BICR: blinded independent central review
- HCP: healthcare professional
- HER2: human epidermal growth factor receptor 2
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- PFS: progression-free survival
- RECIST: Response Evaluation Criteria in Solid Tumors
- T-DXd: trastuzumab deruxtecan

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 49 | Paid |
| Who said each statement: the cited speakers | 8 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 8 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 10 | Free |
| Sources with links | 10 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 3 of the 8 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

10 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR) | discussed | 3 | 3 |
| Secondary endpoints | discussed | 3 | 3 |
| Population and setting | discussed | 11 | 5 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 9 | 3 |
| Safety and tolerability | discussed | 9 | 6 |
| Design and conduct | discussed | 6 | 2 |
| Proposed biological rationale for zanidatamab after T-DXd | discussed | 5 | 2 |
| Earlier zanidatamab evidence in advanced or pretreated breast cancer | discussed | 10 | 6 |
| Trial access, referral and reasons to consider participation | discussed | 9 | 4 |
| Sequencing, resistance and patient priorities across treatment | discussed | 5 | 2 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 36 statements · 74%** | | | |
| YouTube | 36 | 3 | 3 |
| **Posts · 11 statements · 22%** | | | |
| X threads | 11 | 6 | 13 |
| Bluesky threads | 0 | 0 | 2 |
| **Primary sources · 2 statements · 4%** (cited for context, not screened) | | | |
| Registry (primary source, cited for context) | 2 | 1 | not screened |

- Screened window: 2024-12-03 to 2026-10-16
- Cited window: 2024-12-13 to 2026-10-16
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
- Registry: NCT06435429 (https://clinicaltrials.gov/study/NCT06435429)
- Study IDs: JZP598-303 · 2023-508960-31-00 (EU CTR)
- Sponsor: Jazz Pharmaceuticals
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 550 (estimated)
- Start: 2024-08-13 (actual)
- Primary completion: 2028-04-28 (estimated)
- Primary endpoint: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR) (Until disease progression or death, up to approximately 44 months)
- Intervention: Zanidatamab (drug)
- Intervention: Trastuzumab (drug)
- Intervention: Eribulin (drug)
- Intervention: Vinorelbine (drug)
- Intervention: Gemcitabine (drug)
- Intervention: Capecitabine (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 21 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 32 sources about other trials or topics are not included.
- The sources reviewed do not include an EmpowHER-303 outcome dataset. Earlier-phase activity, mechanistic expectations and participation counseling cannot establish comparative efficacy or safety in its post-T-DXd population.
- No separate protocol or exact-trial results publication was identified for this edition. The complete eligibility criteria therefore cannot be reconciled from these discussions alone.
- Searches emphasized explicit trial names and identifiers and may miss unnamed references or differently transcribed discussion. Absence of a criticism here does not establish that no such criticism exists.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- A speaker is described in the sources as presenting EmpowHER-303. Their views should not be counted as an independent external endorsement of the study.
- A YouTube channel publisher describes an AI-generated avatar. Its narration has no proven individual speaker and includes a control-treatment description that conflicts with the registry.
- Reposts are not additional independent clinical opinions. Neither source counts nor favorable comments establish consensus.
- The sources reviewed do not establish a complete current regulatory picture across indications and countries; the video's approval wording remains a dated source statement.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 49 verified statements · 28 from 3 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (8 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/empowher-303-nct06435429
- Agents: POST https://www.erudio.com/api/orders with {"report": "empowher-303-nct06435429", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=empowher-303-nct06435429

## Cite

Erudio Health. EmpowHER-303 (NCT06435429): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/empowher-303-nct06435429

## Questions

### How much does the EmpowHER-303 report cost?

One edition costs $750 (Focused · 49 verified statements · 28 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the EmpowHER-303 report cover?

49 statements from 10 sources (3 videos, 6 posts, 1 registry record), 28 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the EmpowHER-303 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "empowher-303-nct06435429" }) previews it and create_order({ "report": "empowher-303-nct06435429", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the EmpowHER-303 report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/empowher-303-nct06435429.json
- Markdown: https://www.erudio.com/reports/empowher-303-nct06435429.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/empowher-303-nct06435429/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "empowher-303-nct06435429"}`
